Gonzalez-Neira A

References (4)

Title : Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus - Lawrenson_2016_Nat.Commun_7_12675
Author(s) : Lawrenson K , Kar S , McCue K , Kuchenbaeker K , Michailidou K , Tyrer J , Beesley J , Ramus SJ , Li Q , Delgado MK , Lee JM , Aittomaki K , Andrulis IL , Anton-Culver H , Arndt V , Arun BK , Arver B , Bandera EV , Barile M , Barkardottir RB , Barrowdale D , Beckmann MW , Benitez J , Berchuck A , Bisogna M , Bjorge L , Blomqvist C , Blot W , Bogdanova N , Bojesen A , Bojesen SE , Bolla MK , Bonanni B , Borresen-Dale AL , Brauch H , Brennan P , Brenner H , Bruinsma F , Brunet J , Buhari SA , Burwinkel B , Butzow R , Buys SS , Cai Q , Caldes T , Campbell I , Canniotto R , Chang-Claude J , Chiquette J , Choi JY , Claes KB , Cook LS , Cox A , Cramer DW , Cross SS , Cybulski C , Czene K , Daly MB , Damiola F , Dansonka-Mieszkowska A , Darabi H , Dennis J , Devilee P , Diez O , Doherty JA , Domchek SM , Dorfling CM , Dork T , Dumont M , Ehrencrona H , Ejlertsen B , Ellis S , Engel C , Lee E , Evans DG , Fasching PA , Feliubadalo L , Figueroa J , Flesch-Janys D , Fletcher O , Flyger H , Foretova L , Fostira F , Foulkes WD , Fridley BL , Friedman E , Frost D , Gambino G , Ganz PA , Garber J , Garcia-Closas M , Gentry-Maharaj A , Ghoussaini M , Giles GG , Glasspool R , Godwin AK , Goldberg MS , Goldgar DE , Gonzalez-Neira A , Goode EL , Goodman MT , Greene MH , Gronwald J , Guenel P , Haiman CA , Hall P , Hallberg E , Hamann U , Hansen TV , Harrington PA , Hartman M , Hassan N , Healey S , Heitz F , Herzog J , Hogdall E , Hogdall CK , Hogervorst FB , Hollestelle A , Hopper JL , Hulick PJ , Huzarski T , Imyanitov EN , Isaacs C , Ito H , Jakubowska A , Janavicius R , Jensen A , John EM , Johnson N , Kabisch M , Kang D , Kapuscinski M , Karlan BY , Khan S , Kiemeney LA , Kjaer SK , Knight JA , Konstantopoulou I , Kosma VM , Kristensen V , Kupryjanczyk J , Kwong A , de la Hoya M , Laitman Y , Lambrechts D , Le N , De Leeneer K , Lester J , Levine DA , Li J , Lindblom A , Long J , Lophatananon A , Loud JT , Lu K , Lubinski J , Mannermaa A , Manoukian S , Le Marchand L , Margolin S , Marme F , Massuger LF , Matsuo K , Mazoyer S , McGuffog L , McLean C , McNeish I , Meindl A , Menon U , Mensenkamp AR , Milne RL , Montagna M , Moysich KB , Muir K , Mulligan AM , Nathanson KL , Ness RB , Neuhausen SL , Nevanlinna H , Nord S , Nussbaum RL , Odunsi K , Offit K , Olah E , Olopade OI , Olson JE , Olswold C , O'Malley D , Orlow I , Orr N , Osorio A , Park SK , Pearce CL , Pejovic T , Peterlongo P , Pfeiler G , Phelan CM , Poole EM , Pylkas K , Radice P , Rantala J , Rashid MU , Rennert G , Rhenius V , Rhiem K , Risch HA , Rodriguez G , Rossing MA , Rudolph A , Salvesen HB , Sangrajrang S , Sawyer EJ , Schildkraut JM , Schmidt MK , Schmutzler RK , Sellers TA , Seynaeve C , Shah M , Shen CY , Shu XO , Sieh W , Singer CF , Sinilnikova OM , Slager S , Song H , Soucy P , Southey MC , Stenmark-Askmalm M , Stoppa-Lyonnet D , Sutter C , Swerdlow A , Tchatchou S , Teixeira MR , Teo SH , Terry KL , Terry MB , Thomassen M , Tibiletti MG , Tihomirova L , Tognazzo S , Toland AE , Tomlinson I , Torres D , Truong T , Tseng CC , Tung N , Tworoger SS , Vachon C , van den Ouweland AM , van Doorn HC , van Rensburg EJ , Van't Veer LJ , Vanderstichele A , Vergote I , Vijai J , Wang Q , Wang-Gohrke S , Weitzel JN , Wentzensen N , Whittemore AS , Wildiers H , Winqvist R , Wu AH , Yannoukakos D , Yoon SY , Yu JC , Zheng W , Zheng Y , Khanna KK , Simard J , Monteiro AN , French JD , Couch FJ , Freedman ML , Easton DF , Dunning AM , Pharoah PD , Edwards SL , Chenevix-Trench G , Antoniou AC , Gayther SA
Ref : Nat Commun , 7 :12675 , 2016
PubMedID: 27601076

Title : Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM\/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis - Martin_2015_Oncologist_20_111
Author(s) : Martin M , Martinez N , Ramos M , Calvo L , Lluch A , Zamora P , Munoz M , Carrasco E , Caballero R , Garcia-Saenz JA , Guerra E , Caronia D , Casado A , Ruiz-Borrego M , Hernando B , Chacon JI , De la Torre-Montero JC , Jimeno MA , Heras L , Alonso R , De la Haba J , Pita G , Constenla M , Gonzalez-Neira A
Ref : Oncologist , 20 :111 , 2015
PubMedID: 25601966

Title : A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome - Caronia_2011_Clin.Cancer.Res_17_2006
Author(s) : Caronia D , Martin M , Sastre J , de la Torre J , Garcia-Saenz JA , Alonso MR , Moreno LT , Pita G , Diaz-Rubio E , Benitez J , Gonzalez-Neira A
Ref : Clin Cancer Research , 17 :2006 , 2011
PubMedID: 21325291

Title : Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009-05 study - Martin_2011_J.Clin.Oncol_29_1008
Author(s) : Martin M , Martinez N , Ramos M , Calvo L , Lluch A , Zamora P , Munoz-Mateu M , Caronia D , Carrasco EM , Garcia Saenz JA , Casado A , Chacon I , Hernando B , Ruiz-Borrego M , Gonzalez-Neira A
Ref : J Clin Oncol , 29 :1008 , 2011
PubMedID: 28020778